

Addendum

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma**Yongshun Chen^{1,2}, Xiaoyuan Wu², Daxuan Hao², Xinyu Cheng², Lei Zhang³, Yougai Zhang², Shaobo Ke¹, Wei Shi¹ and Chunyu He²**¹Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China²Department of Radiation Oncology, Zhengzhou University Affiliated Cancer Hospital, Zhengzhou, China³Department of Nephrology, People's Hospital of Tibet Autonomous Region, Tibet Autonomous Region, Lhasa, China**Published:** December 06, 2022**Copyright:** © 2022 Chen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** This observational study was summarized from clinical data, therefore the patients' informed consents were waived. This study was approved by the Ethics Committee.Original article: Oncotarget. 2019; 10:4069–4078. <https://doi.org/10.18632/oncotarget.23861>